The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Patients with axSpA who received UPA reported rapid and sustained improvements in total and nocturnal back pain over 12 weeks.

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

A painkiller developed by Germany's Algiax Pharma has shown efficacy in the treatment of chronic neuropathic pain, another positive development in the search for alternatives to opioids. The phase ...

Chronic pain in India linked to suicide risk, overlooked in mental health assessments, highlighting need for integrated care.

According to the global market research firm Frost & Sullivan, the scale of the cell and gene therapy market is expected to grow more than threefold, from $16.33 billion in 2023 (approximately 23. ...

Spinal cord stimulation (SCS) effectively relives pain and restores nerve function in patients with painful diabetic peripheral neuropathy (DPN), according to the findings of a small study ...

Weak correlations were found between the S-LANSS score and MSK-HQ score, the numerical rating scale (0–10) values for ‘average pain’ and for ‘worst pain’, but not with the MSK-HQ %health ...

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which ...

Chronic pain affects millions of people in the US. Targeting an oft-overlooked brain receptor could one day offer relief.